-
公开(公告)号:US10555995B2
公开(公告)日:2020-02-11
申请号:US15569641
申请日:2016-04-29
发明人: Ben Hause , Emily Collin , Ying Fang , Lalitha Peddireddi
摘要: Porcine pestivirus designated herein as atypical porcine pestivirus (“APPV”) (Genbank accession no. KR011347.1). Immunogenic compositions to induce an immune response against porcine pestivirus infection in a pig are described, which APPV antigenic agents (e.g., isolated whole virus, derivatives thereof, functional fragments thereof, and combinations of the foregoing). Methods of vaccinating against porcine pestivirus infection using the immunogenic compositions are also described. The methods can be also applied for clinical research and/or study, including diagnostic methods for detecting pestivirus infection using monoclonal antibodies specifically binding to APPV epitopes.
-
公开(公告)号:US20180303926A1
公开(公告)日:2018-10-25
申请号:US15569641
申请日:2016-04-29
发明人: Ben Hause , Emily Collin , Ying Fang , Lalitha Peddireddi
IPC分类号: A61K39/12 , C12Q1/70 , A61P31/12 , G01N33/569 , A61K39/42
CPC分类号: A61K39/12 , A61K39/42 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61P31/12 , C12N2770/24134 , C12Q1/70 , G01N33/569
摘要: Porcine pestivirus designated herein as atypical porcine pestivirus (“APPV”) (Genbank accession no. KR011347.1). Immunogenic compositions to induce an immune response against porcine pestivirus infection in a pig are described, which APPV antigenic agents (e.g., isolated whole virus, derivatives thereof, functional fragments thereof, and combinations of the foregoing). Methods of vaccinating against porcine pestivirus infection using the immunogenic compositions are also described. The methods can be also applied for clinical research and/or study, including diagnostic methods for detecting pestivirus infection using monoclonal antibodies specifically binding to APPV epitopes.
-
3.
公开(公告)号:US20210162039A1
公开(公告)日:2021-06-03
申请号:US17250020
申请日:2019-05-13
发明人: Weiping Zhang , Ying Fang
IPC分类号: A61K39/225 , A61K39/108 , C07K14/165
摘要: The present disclosure provides vaccines or immunogenic compositions against clinical signs, symptoms, and losses attributable to or caused by infection with PEDV and/or ETEC. Antigenic epitopes from PEDV and ETEC are used to construct an immunogenic composition, preferably in the form of a multi-epitope fusion antigen or as a live strain through E. coli.
-
-